Financials data is unavailable for this security.
View more
Year on year Sun Pharma Advanced Research Co Ltd 's revenues fell -68.36%from 2.39bn to 755.45m. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a 73.96% reduction in net income from a loss of 2.23bn to a larger loss of 3.87bn.
| Gross margin | 59.81% |
|---|---|
| Net profit margin | -568.24% |
| Operating margin | -595.29% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Sun Pharma Advanced Research Co Ltd increased its cash reserves by 813.21%, or 47.46m. Cash Flow from Investing totalled 3.92bn, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 4.29bn for operations while cash generated from financing totalled 424.05m.
| Cash flow per share | -11.60 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
